VV-alpha-CTLA-4

VV-alpha-CTLA-4 appears to refer to an investigational **oncolytic vaccinia virus expressing an anti-CTLA-4 payload**, but I could not verify a unique, formally characterized drug record for this exact code name. Based on the naming pattern, it most likely denotes a vaccinia virus based cancer immunotherapy designed to selectively replicate in tumors, cause oncolysis, and locally deliver CTLA-4 checkpoint blockade to enhance antitumor T-cell responses. However, because the exact asset identity, developer, construct details, clinical status, and formal nomenclature could not be confirmed for this precise name, the entry should be treated as unresolved and non-validated rather than as a definitively identified drug.